AU2008315414A1 - Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) - Google Patents

Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) Download PDF

Info

Publication number
AU2008315414A1
AU2008315414A1 AU2008315414A AU2008315414A AU2008315414A1 AU 2008315414 A1 AU2008315414 A1 AU 2008315414A1 AU 2008315414 A AU2008315414 A AU 2008315414A AU 2008315414 A AU2008315414 A AU 2008315414A AU 2008315414 A1 AU2008315414 A1 AU 2008315414A1
Authority
AU
Australia
Prior art keywords
vegf
antibody
angiogenic
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008315414A
Other languages
English (en)
Inventor
David O. Bates
Steven J. Harper
Miriam Y. Mangelus
Menachem Ze'evi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Philogene Inc
Original Assignee
University of Bristol
Philogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol, Philogene Inc filed Critical University of Bristol
Publication of AU2008315414A1 publication Critical patent/AU2008315414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008315414A 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) Abandoned AU2008315414A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98243807P 2007-10-25 2007-10-25
US60/982,438 2007-10-25
PCT/IL2008/001410 WO2009053987A1 (en) 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)

Publications (1)

Publication Number Publication Date
AU2008315414A1 true AU2008315414A1 (en) 2009-04-30

Family

ID=40385456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008315414A Abandoned AU2008315414A1 (en) 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)

Country Status (7)

Country Link
US (1) US8592563B2 (https=)
EP (1) EP2203480A1 (https=)
JP (1) JP2011504092A (https=)
CN (1) CN101970486A (https=)
AU (1) AU2008315414A1 (https=)
CA (1) CA2703154A1 (https=)
WO (1) WO2009053987A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US20130034861A1 (en) * 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CA2837914A1 (en) * 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP6675687B2 (ja) * 2015-05-29 2020-04-01 国立大学法人名古屋大学 尿中ＶＥＧＦ−Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7820178B2 (en) * 2001-08-01 2010-10-26 University of Brisol VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
US20050009110A1 (en) 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
AU2006242449A1 (en) * 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080031815A1 (en) * 2006-07-27 2008-02-07 Xiaoyuan Chen Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments

Also Published As

Publication number Publication date
EP2203480A1 (en) 2010-07-07
CN101970486A (zh) 2011-02-09
WO2009053987A1 (en) 2009-04-30
US20100272733A1 (en) 2010-10-28
CA2703154A1 (en) 2009-04-30
JP2011504092A (ja) 2011-02-03
US8592563B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
US8592563B2 (en) Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)
US9795672B2 (en) Treatment with anti-VEGF antibodies
AU2011221229B2 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
DK2361085T3 (en) Using anti-VEGF antibody in combination with chemotherapy for treatment of breast
US20100266589A1 (en) Adjuvant cancer therapy
WO2011143408A1 (en) Use of neuropilin-1 antagonists for the treatment of cancer
US20190309031A1 (en) Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
WO2011153243A2 (en) Anti-angiogenesis therapy for treating gastric cancer
US20070036755A1 (en) Treatment with anti-vegf antibodies
AU2018214131A1 (en) Treatment with anti-VEGF antibodies
AU2012204035B2 (en) Treatment with anti-VEGF antibodies
AU2015203013A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
HK1172839A (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
HK1144202A (en) Treatment with anti-vegf antibodies
HK1144290A (en) Treatment with anti-vegf antibodies

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application